Hodgkin's Lymphoma (HL)
Hodgkin's lymphoma, named after Thomas Hodgkin who first described it in the 19th century, is a relatively rare form of cancer that primarily affects young adults. At our company, we take immense pride in our expertise in Hodgkin's lymphoma (HL) therapy and animal model development. As a leader in the industry, we offer a range of customized services tailored to meet the specific requirements of biology researchers.
Introduction to Hodgkin's Lymphoma (HL)
Hodgkin's lymphoma (HL) is a type of lymphoma that originates in the lymphatic system, which is part of the body's immune system. It is characterized by the presence of Reed-Sternberg cells, large abnormal cells that are typically derived from B lymphocytes. These cells are surrounded by an inflammatory background, consisting of various immune cells and a complex microenvironment that supports their survival and growth. HL is further classified into two main subtypes: classical Hodgkin's Lymphoma (cHL) and nodular lymphocyte-predominant Hodgkin's Lymphoma (NLPHL). cHL accounts for the majority of cases and is characterized by the presence of Reed-Sternberg cells, while NLPHL is characterized by the presence of lymphocyte-predominant cells.
Fig.1 Mechanism of drug action of MZL. (Cheah, Chan Y., et al., 2022)Types of Hodgkin's Lymphoma (HL)
Classical Hodgkin's Lymphoma (CHL)
Classical Hodgkin's lymphoma (CHL) is the most common subtype of HL, accounting for about 95% of cases. It is characterized by the presence of Reed-Sternberg cells surrounded by a background of inflammatory cells, including lymphocytes, plasma cells, eosinophils, and histiocytes. cHL is further divided into four subtypes: nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted. Each subtype has its own distinct pathological and features.
Nodular Lymphocyte-Predominant Hodgkin's Lymphoma (NLPHL)
Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a less common subtype of HL, accounting for approximately 5% of cases. It is characterized by the presence of large, popcorn-shaped lymphocyte-predominant cells known as L&H cells. Compared to cHL, NLPHL has a more indolent course and a better prognosis. The histopathological features of NLPHL include nodular architecture with a background of small lymphocytes, plasma cells, and histiocytes.
Therapeutic Strategies for HL
Early favorable people with cHL typically receive two cycles of ABVD chemotherapy followed by involved field radiotherapy (IFRT) with 20 Gy. On the other hand, early unfavorable people usually undergo four cycles of ABVD chemotherapy followed by IFRT with 30 Gy. The therapy approach for advanced-stage HL is more controversial, with the standard of care being six to eight cycles of ABVD chemotherapy. However, the more effective but also more toxic BEACOPPescalated approach is being increasingly adopted. Novel drugs, such as brentuximab vedotin, have also shown efficacy in relapsed HL people, providing an additional therapy option.
Our Services
With a team of highly skilled and knowledgeable scientists who specialize in the development of innovative therapies for Hodgkin's lymphoma, we provide end-to-end solutions, from diagnostics to therapy development. Whether you require assistance with target validation, drug screening, or therapeutic efficacy studies, our team will work closely with you to design and execute a research plan that aligns with your objectives.
Study Types of Hodgkin's Lymphoma (HL)
Platforms of HL Therapy Development
We have an extensive collection of well-characterized animal models specifically designed for Hodgkin's lymphoma research. These models accurately recapitulate the disease characteristics and allow for the evaluation of novel drugs and therapies. Our diverse range of animal models enables researchers to conduct in-depth studies, including drug safety assessments and intricate pharmacokinetic analyses. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Cheah, Chan Y., et al. "Marginal zone lymphoma: present status and future perspectives." Haematologica 107.1 (2022): 35.
- Weniger, Marc A., and Ralf Küppers. "Molecular biology of Hodgkin lymphoma." Leukemia 35.4 (2021): 968-981.
- Ansell, Stephen M. "Hodgkin lymphoma: diagnosis and treatment." Mayo Clinic Proceedings. Vol. 90. No. 11. Elsevier, 2015.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.